Most Read Articles
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

Podcast: Prof Peter Schmid speaks on PFS benefit with atezolizumab-chemo combo in triple negative breast cancer in IMpassion130

29 Oct 2018
Podcast: Prof Peter Schmid speaks on PFS benefit with atezolizumab-chemo combo in triple negative breast cancer in IMpassion130
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).